Zhejiang Ausun Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) on January 27, 2025: 3.21

Zhejiang Ausun Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) is 3.21 on January 27, 2025, a 51.66% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Zhejiang Ausun Pharmaceutical Co., Ltd. 52-week high Price to Book Ratio (P/B) is 4.19 on January 06, 2025, which is 30.54% above the current Price to Book Ratio (P/B).
Zhejiang Ausun Pharmaceutical Co., Ltd. 52-week low Price to Book Ratio (P/B) is 1.64 on February 05, 2024, which is -48.86% below the current Price to Book Ratio (P/B).
Zhejiang Ausun Pharmaceutical Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 2.53.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd.

CEO	Mr. Zhiguo Zheng
IPO Date	May 9, 2017
Location	China
Headquarters	No. 5 Donghai Fourth Lane
Employees	1,174
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials

Description

Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.

Key trends

Past 5 years